Cohort | Risk cluster | P valuea | ||||
---|---|---|---|---|---|---|
Total | Low | Medium | High | |||
Training set | ||||||
Stockholm | n | 159 | 49 | 51 | 59 | |
5-year eventb | 38 (24%) | 2 (4.2%) | 7 (14%) | 29 (49%) | <10-7 | |
Treated with adjuvant therapy | ||||||
Stockholm tamoxifen only | N c | 104 | 38 | 33 | 33 | |
5-year event | 22 (21%) | 0 (0%) | 6 (18%) | 16 (48%) | <10-6 | |
Uppsala node-positive | n | 76 | 14 | 27 | 35 | |
5-year event | 33 (43%) | 2 (14%) | 10 (37%) | 21 (60%) | 0.002 | |
Untreated with adjuvant therapy | ||||||
Stockholm | n c | 33 | 7 | 10 | 16 | |
5-year event | 11 | 1 (14%) | 0 (0%) | 11 (69%) | 0.002 | |
Uppsala node-negative | n | 135 | 51 | 55 | 29 | |
5-year event | 17 (12%) | 3 (5.8%) | 7 (13%) | 7 (24%) | 0.02 | |
Van't veer | n | 78d | 19 | 33 | 25 | |
5-year event | 33 | 2 (17%) | 18 (53%) | 13 (55%) | 0.01 |